Multiple roles of HDAC inhibition in neurodegenerative conditions

By D. Chuang, Y. Leng, Z. Marinova, H. Kim, C. Chiu. Trends in Neurosciences, 2009

643 citations recorded by the source corpus.

Histone deacetylases (HDACs) play a key role in homeostasis of protein acetylation in histones and other proteins and in regulating fundamental cellular activities such as transcription. Imbalances in protein acetylation levels and dysfunctions in transcription are associated with a wide variety of brain disorders. Treatment with various HDAC inhibitors corrects these deficiencies and has emerged as a promising new strategy for therapeutic intervention in neurodegenerative diseases. Here, we review and discuss intriguing recent developments in the use of HDAC inhibitors to combat neurodegenerative conditions in cellular and disease models. HDAC inhibitors have neuroprotective, neurotrophic and anti-inflammatory properties, and improvements in neurological performance, learning/memory and other disease phenotypes are frequently seen in these models. We discuss the targets and mechanisms underlying these effects of HDAC inhibition and comment on the potential for some HDAC inhibitors to prove clinically effective in treating neurodegenerative disorders.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/2b11d37b7d5c4524eefadd6ea0f3a9257135fd1f

Citations in the corpus

• Molecular mechanisms of diabetic cardiomyopathy (2014, neutral): “Dysregulation of histone acetylation contributes to the development of a variety of diseases, and HDAC inhibition is a widely discussed therapeutic option to potentially treat a multitude of prevalent diseases such as cancer and neurodegenerative, inflammatory and cardiovascular disorders [135–137].”